Citius Pharmaceuticals Introduces Permanent J-Code for LYMPHIR to Enhance Patient Access Citius Pharmaceuticals announces the issuance of a permanent J-code for LYMPHIR, facilitating better access and reimbursement for patients suffering from cutaneous T-cell lymphoma.

Citius Pharmaceuticals Introduces Permanent J-Code for LYMPHIR to Enhance Patient Access #USA #Citius_Pharma #Cranford #LYMPHIR #J9161

Citius Pharmaceuticals Implements 1-for-25 Reverse Stock Split to Enhance Share Value Citius Pharmaceuticals has announced a 1-for-25 reverse stock split to boost its stock price above the minimum requirement for Nasdaq listing, effective November 25, 2024.

Citius Pharmaceuticals Implements 1-for-25 Reverse Stock Split to Enhance Share Value #United_States #Citius_Pharma #Stock_Split #CTXR #Cranford